Register for our free email digests:
While attention has been focused on other products, Alnylam is set to take another RNAi product candidate – givosiran – into pivotal testing following positive early data in acute hepatic porphyria.
The increasing threat of treatment-resistant Candida auris fungal infections suggests the need for greater development incentives, CEOs of three antifungal drug developers told the recent BIO annual meeting.
In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Civen; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.
Shame has historically been used as an effective tool in bringing about a change in pricing policy within an industry. But could it be wielded against the pharma industry today? Viren Mehta, founding partner of Mehta Partners, LLC, considers.
Recent Tweets from Scrip
Tweets from https://twitter.com/IBI_Tweets/lists/scrip-tweets
Commercial Explore this Topic
As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.
Emerging Company Profile: The new anticancer antibody developer ImCheck Therapeutics has set up in Marseille, France, a location that is becoming increasingly attractive to biotech start-ups that could rival more established areas in coming years.
Latest From Commercial
Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.
Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.
BIO International 2017 discussion: growing a biotech business. Informa's global content editor Mike Ward discusses how to scale up your SME and access international markets with experts in the field. This content was produced by Scrip alongside a sponsored project with MSP, a provider of specialized science campuses in Manchester and Cheshire, UK.
Lupin’s founder and chairman, Desh Bandhu Gupta, who died aged 79 on June 26, was known to give employees significant autonomy at the workplace, with some saying that people were the crux of his company-building mantra.
Policy & Regulation Explore this Topic
Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.
Although South Korea has a good clinical trial infrastructure, workforce, and novel drug development technology, it still lacks the power to lead the development of new drugs across the finish line. The country needs to create an environment that can attract multinationals to co-research and co-develop drugs with domestic pharma firms under open innovation programs if Korea-originated blockbusters are ever to emerge, experts told a recent forum in Seoul.
US agency unveils plans to speed reviews of generic applications in areas with limited competition and offers a list of potential targets, but threat to brands may be limited.
AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.
Research & Development Explore this Topic
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
Latest From Research & Development
Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.
Dr. Shuang Liu, president and co-founder of ConSynance Therapeutics, talks with Scrip’s Brian Yang about the US-based startup's plans to develop and commercialize in China its assets for indications including NASH.
Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.